EPLAW PATENT BLOG

CJEU – Abraxis Bioscience v. Comptroller General of Patents / SPC

Posted: March 22nd, 2019

Abraxis Bioscience LLC v. Comptroller General of Patents, Court of Justice of the EU, 21 March 2019, Case no. C‑443/17

No SPC for a new formulation of an old active ingredient

“Article 3(d) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products, read in conjunction with Article 1(b) of that regulation, must be interpreted as meaning that the marketing authorisation referred to in Article 3(b) of that regulation, relied on in support of an application for a supplementary protection certificate concerning a new formulation of an old active ingredient, cannot be regarded as being the first marketing authorisation for the product concerned as a medicinal product in the case where that active ingredient has already been the subject of a marketing authorisation as an active ingredient.”

Leave a Reply